Sexual Supplement Claims Don’t Stand Up Under Evidence – CBBB Group
The Daily Wellness Company should revise quantitative and exclusivity claims for its sexual supplement ArginMax because supporting evidence is insufficient, the Electronic Retailing Self-Regulation Program (ERSP) concludes
More from Archive
More from Pink Sheet
Pink Sheet reporter and editors discuss the most recent senior staff departures at the FDA and their impact on the agency, as well as Commissioner Martin Makary’s plans for a new approval pathway and a combined adverse event database as outlined in an interview with a podcast host.
The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.